At a glance
ClinicalIndex Comparison RecordPhase 3Active· 19 enrolled / 19 target
Drug / intervention
JNJ-77242113drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
In Brief
A Phase 3 clinical trial evaluating JNJ-77242113 for Generalized Pustular Psoriasis and Erythrodermic Psoriasis. Active but no longer recruiting, targeting 19 participants across 12 sites.
Signals
Enrollment appears stalled
Detailed Summary
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 3Active
202520262027
Enrollment StartFeb 2024
First PostedMar 2024
Primary CompletionJan 2025
TodayJul 2026
Study CompletionOct 2027
First PostedMar 6, 2024
Enrollment StartFeb 9, 2024
Primary CompletionJan 14, 2025
Study CompletionOct 14, 2027
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.3 years ago
Arms & Interventions
JNJ-77242113- Participants With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP)experimental
Participants with GPP or EP will receive JNJ-77242113 tablet orally.
Drug: JNJ-77242113
Interventions
JNJ-77242113drug
JNJ-77242113 tablet will be administered orally.